TMEM63B

Across TCGA pan-cancer cohorts, TMEM63B mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated TMEM63B data layer compared with 19 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TMEM63B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMEM63B expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

LUAD, HNSC, and PDAC are the cancer types where TMEM63B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.773	1.000	.005	16	view →
HNSC	DFS	Quartile	II,III,IV	0.991	0.876	.025	13	view →
PDAC	OS	Tertile	III,IV	0.721	0.245	.003	13	view →
CCRCC	DFS	Median	III,IV	0.772	0.423	.013	11	view →
UCEC	DFS	Tertile	II,III,IV	1.000	0.488	.009	8	view →
LSCC	OS	Tertile	II,III,IV	1.000	0.846	.022	5	view →
GBM	DFS	Median	All	0.833	0.668	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

TMEM63B–LUAD (DFS)

Open the LUAD breakdown →